In recent developments, HC Wainwright & Co. has maintained its 'Buy' rating for Cognition Therapeutics (CGTX, Financial), while lowering its price target from $5.00 to $3.00. This adjustment, reported on May 27, 2025, reflects a 40% decrease in the previously anticipated price target.
The analyst behind the decision, Raghuram Selvaraju, has upheld the 'Buy' rating despite the adjustment in the price target, signaling continued confidence in CGTX's potential within the market. The lowered price target is part of HC Wainwright & Co.'s latest assessment of the company's projected performance.
As of the announcement, the current price target for CGTX stands at $3.00 USD, down from the prior $5.00 USD. Investors in Cognition Therapeutics will be closely monitoring how the company navigates this updated outlook and the implications it may have on their investments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cognition Therapeutics Inc (CGTX, Financial) is $5.40 with a high estimate of $8.00 and a low estimate of $2.00. The average target implies an upside of 1,718.79% from the current price of $0.30. More detailed estimate data can be found on the Cognition Therapeutics Inc (CGTX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Cognition Therapeutics Inc's (CGTX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
